Moberg Pharma AB (publ) (MOB.ST) Research

Moberg Pharma AB (publ) functions as a pharmaceutical company, dedicated to both crafting and globally marketing medical solutions throughout Europe, the United States, and various international territories. A notable product within its development portfolio is MOB-015, a treatment designed for nail fungus, which has successfully concluded its Phase III clinical trials. Established in 2006, this enterprise is headquartered in Bromma, Sweden. It was previously known as Moberg Derma AB (publ) until its rebranding to the current name in May 2013.

Market snapshot

Symbol
MOB.ST
Price
$9.24
Day change
+0.43%
Market cap
$434.3M
P/E ratio
-16.84x
52-week range
7.53-14.12
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Next earnings
in 2 months

Peer companies

  • Acarix AB (publ) (ACARIX.ST)
  • Ascelia Pharma AB (publ) (ACE.ST)
  • AlzeCure Pharma AB (publ) (ALZCUR.ST)
  • Enzymatica AB (publ) (ENZY.ST)
  • Enorama Pharma AB (publ) (ERMA.ST)
  • Mendus AB (publ) (IMMU.ST)
  • Intervacc AB (publ) (IVACC.ST)
  • Klaria Pharma Holding AB (publ.) (KLAR.ST)

Open Moberg Pharma AB (publ) (MOB.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.